Realta Investment Advisors Sells 495 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Realta Investment Advisors cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,668 shares of the biopharmaceutical company’s stock after selling 495 shares during the period. Realta Investment Advisors’ holdings in Gilead Sciences were worth $335,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GILD. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter worth about $25,000. YANKCOM Partnership acquired a new position in Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC boosted its position in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.6 %

GILD stock opened at $98.04 on Friday. The stock’s 50 day simple moving average is $92.97 and its 200 day simple moving average is $86.49. The company has a market cap of $122.18 billion, a P/E ratio of 1,089.33, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $100.51.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business earned $2.29 EPS. Gilead Sciences’s quarterly revenue was up 7.0% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price on the stock. Bank of America restated a “buy” rating and issued a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.